Form 4: Heron Therapeutics Executive Reports Stock Transactions

Heron Therapeutics, Inc. executive Craig Collard reported transactions involving common stock and restricted stock units.

Summary

• Craig Collard, Chief Executive Officer and Director of Heron Therapeutics, Inc., reported transactions on April 30, 2026.
• Collard acquired 34,789 shares of common stock and 34,789 restricted stock units (RSUs).
• Additionally, Collard acquired 50,021 shares of common stock and 50,021 RSUs.
• Following these transactions, Collard beneficially owns 696,841 shares of common stock directly.
• The RSUs vest in 16 equal installments starting one quarter after the grant date.
• A grant of 800,337 RSUs was made on January 30, 2026, with a similar vesting schedule.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider stock transactions and compensation-related grants rather than significant strategic or financial performance indicators.

Positives

• Acquisition of common stock and RSUs by a key executive can indicate confidence in the company's future.
• The executive's beneficial ownership of a significant number of shares (696,841) suggests a strong alignment with shareholder interests.

Future Outlook

The vesting schedule for restricted stock units indicates future potential share issuances and compensation realization for the reporting person.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive stock holdings and movements within the biotechnology and pharmaceutical sector.

Stakeholder Impact

• Shareholders: Increased transparency into executive stock ownership and compensation structure.

Next Steps

• Vesting of restricted stock units in installments as per the defined schedule.

Key Dates

Keywords

Heron Therapeutics, HRTX, Form 4, Stock Transaction, Executive Compensation, Restricted Stock Units, Beneficial Ownership, SEC Filing